Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > I'm surprised there hasn't been more discussion about this..

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Jan 26, 2024 5:16pm

92 Views

Post# 35847929

RE:RE:RE:RE:RE:I'm surprised there hasn't been more discussion about this..

"I was thinking more about how existing SBM shareholders have been subordinated". Wrong way of looking at it.

If SBM raised $10M to fund GPM, existing shareholders are diluted by 100M shares.

If SBM created a 50/50 JV where the partner earned its share by inputting $10M SBM would only get 50% of earnings from JV, so again dilution.

If SBM creates SL and sells part of it to new investors to raise $10M then SBM will have an economic interest in SL of less than 100%. Again, dilution.

So you choose the least dilutive option.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario